Project Grant R03AR084585
Award Date
7/19/24
Completion Date
6/30/26
Dollars Obligated
$170K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $343,904 to The Regents of the University of California, San Francisco to investigate transcriptional abnormalities in skin-resident T cells as potential biomarkers for atopic dermatitis in Asian and Hispanic genetic backgrounds. The research aims to validate an abnormal atopic T...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $317,304 to Duke University to develop a digital intervention to promote medication adherence among adolescents with pediatric systemic lupus erythematosus (PSLE). The project aims to: 1) define an objective measure of non-adherence to hydroxychloroquine using pharmacokinetic modeling; 2)...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $100,138.00 to investigate the role of Staphylococcus aureus-induced itch and neuro-immune signaling in driving skin inflammation and atopic dermatitis. The award recipient, President and Fellows of Harvard College (doing business as Harvard Medical School), will conduct research to...
This Project Grant award, totaling $151,444, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research conducted by The Children's Hospital of Philadelphia (CHOP) to model the development of allergic diseases in children using electronic health record (EHR) data. The goals are to (1) determine the major pediatric allergic trajectories and associated risk factors, and...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $385,575 to the University of California, San Diego (UCSD) to investigate the crosstalk between immune dysregulation and impaired wound healing in an inherited autoinflammatory disease called disabling pansclerotic morphea (DPM). The key objectives of this 5-year research project are to: 1) determine the mechanism by...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,297,775 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Denver, Colorado. The funding will support a research project titled "SUNBEAM Birth Cohort: Deciphering the Role of Early Life Skin Dysfunction in Development of the Allergic March." The project aims to evaluate whether early-life skin pathobiology leads to the development of...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $297,940 to Case Western Reserve University from August 15, 2024 to July 31, 2026. The purpose is to develop patient- and parent-driven outcome measures for evaluating glandular inflammation and its flares, and their impact on quality of life and mental health for clinical trials related to...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), provides $486,750 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to establish collaborations and capabilities to advance the study of the exposome in childhood-onset rheumatic diseases and other pediatric autoimmune conditions. The key products and services to be delivered include: Establishing a...
This $664,933 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the cellular and molecular mechanisms of interleukin-17A (IL-17A) in the pathogenesis of psoriatic arthritis. The research aims to define the early cellular and molecular pathways that drive IL-17A-induced joint and skin inflammation, enthesitis, fingernail psoriasis,...